Implication of thromboxane in the pathogenesis of Kawasaki disease and a suggestion for using novel thromboxane synthetase inhibitors in its treatment.
Kawasaki disease, a mucocutaneous lymph node syndrome predominantly prevalent in children, presents with coronary artery aneurysms and thrombocytosis, and investigators have suggested use of anticoagulants in addition to platelet inhibiting drugs. In Kawasaki disease, hypersensitivity reactions due to antigen/antibody complexes (Arthus type III) may damage the vessel wall and induce arteritis, and antigens may be of microbial or viral origin. Since thromboxane has been implicated in the pathogenesis of Kawasaki disease, I suggest use of ginger and carbon dioxide, novel thromboxane synthetase inhibitors. Thromboxane synthetase inhibitors may act as anticoagulants, platelet inhibitors, anti-inflammatory agents, and agents with both antimicrobial and antiviral activity.
Backon
J
J
Mount Pleasant Hospital Addiction Studies Foundation, Lynn, MA.
D002245:Carbon Dioxide / Q000008:administration & dosage; D002648:Child; D006801:Humans; D009080:Mucocutaneous Lymph Node Syndrome / Q000209:etiology* / Q000628:therapy; D010946:Plants, Medicinal; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D013931:Thromboxanes / Q000502:physiology*
D013931:Thromboxanes; D002245:Carbon Dioxide; D013930:Thromboxane-A Synthase